Press release: COVID-19 virus affecting clinical trials in Norway

The restrictions – which also include a temporary halt in patient recruitment for new clinical trials – are implemented at all large hospitals nation-wide and include a provisional standstill in monitoring of ongoing research, as well, consequently delaying its outcomes.

It is imperative to note, that the precautionary measures taken, are in no way related to which studies that are ongoing, which treatment that is researched, or which company that is responsible for conducting it.

Ongoing Dialogue

LMI have contacted the health authorities, requesting advice as to how our members should relate to health personnel and hospital contact, but are yet to receive any information.

LMI, Oslo Cancer Cluster and their members have introduced their own precautionary restrictions for their employees, aiming to limit the risk of spreading the virus and to allow health personnel to prioritise according to the current, extraordinary needs.

LMI and Oslo Cancer Cluster will continue to monitor the situation closely and encourage both members and non-members to report any restrictions they might receive.

About

Oslo Cancer Cluster is a non-profit member organization dedicated to accelerating the development of cancer treatments.

LMI is the pharmaceutical industry association in Norway and consists of Norwegian and international companies that develop, produce, sell or market pharmaceuticals in Norway.

Contact persons

Ketil Widerberg, General Manager, Oslo Cancer Cluster

kw@oslocancercluster.no, +47 915 77 990

Hege Edvardsen, senior advisor, LMI

Hege.edvardsen@lmi.no, + 47 908 68 328